Dr. Koval joins staff at CARD clinic

The Center for Asbestos Related Diseases announces the addition of Dr. Alisa Koval, from National Jewish Health in Denver in the Department of Environmental & Occupational Health Sciences.  

Dr. Koval will play a key role in the CARD organization by providing  asbestos related health screenings and chronic asbestos disease management for patients one week each month.  

She also is an active participant in the Libby Epidemiological Research Program. Her research interests include the characterization of pulmonary and autoimmune disease presentation associated with Libby amphibole asbestos.

Kovalis a recent graduate of the Occupational & Environmental Medicine Residency program at the Mount Sinai School of Medicine in New York City where she worked closely with Dr. Stephen Levin.  She has been focusing on Libby amphibole asbestos for the past 2 ½ years.  

She began her education at the University of Michigan, earning a bachelor of science in biology with honors, followed by a master of health service administration. After spending a year as an administrative fellow at The Children’s Hospital of Denver, she went on to earn her MD from the Georgetown University School of Medicine.  

Prior to beginning her residency training, she worked as an internal consultant at New York-Presbyterian Hospital in their Six Sigma program.  She stayed on to complete her training in general preventive medicine & public health.

Dr. Brad Black, medical director and CEO of CARD, said “we are excited to have Dr. Koval join our patient care team at CARD.  Her commitment to the people of Libby and her knowledge of Libby amphibole asbestos will be a great asset to CARD patients.”

CARD is devoted to healthcare, education, outreach and research to benefit all people impacted by exposure to Libby amphibole asbestos.  

During the past few years,  the Center for Asbestos Related Disease has emerged as a national center of excellence in addressing healthcare issues associated with Libby amphibole. We look forward to providing caring pathways to treatment now and in the future.